Dr. Molly Davis, MD

I graduated with distinction from Stanford University, earning a B.S. in Human Biology. I received my M.D. from the University of Washington School of Medicine in 2001 and completed a general psychiatry residency and geriatric psychiatry fellowship at Oregon Health & Science University (OHSU), where I served as chief resident in my final year. I am board-certified in both general and geriatric psychiatry.

After my training, I joined the OHSU faculty as a geriatric psychiatrist. My specialties include treating refractory mood disorders with electroconvulsive therapy (ECT), evaluating and treating major neurocognitive disorders (dementia), and diagnosis and treatment of movement disorders. I have additional training in neurology and movement disorders. I have worked in various inpatient and outpatient psychiatric settings. Since 2014, my focus has been on using deep transcranial magnetic stimulation (dTMS) to treat treatment-resistant mental illness.

Currently, I am thrilled to have co-founded Clear Path Psychiatry with Dr. Eliza Brink, PMHNP + DNP. Clear Path is an innovative interventional psychiatry practice in Seattle, Washington. We offer deep rTMS to treat treatment-resistant depression and obsessive-compulsive disorder, using the BrainsWay H1 and H7 coils. We also provide Spravato (intranasal esketamine) as an augmenting agent for patients suffering from treatment-resistant depression or depression with suicidal thoughts. 

In 2018, I immersed myself in studying psychedelic medicine. I am trained through the Multidisciplinary Association for Psychedelic Studies (MAPS) to offer MDMA-assisted therapy for individuals with treatment-resistant PTSD pending FDA approval. I completed a year-long fellowship through the Integrative Psychiatry Institute in psychedelic-assisted therapy and am eager to offer psychedelic medicines as they gain FDA approval.

Beyond my professional pursuits, my personal journey has equipped me with a unique perspective on navigating life as a patient. Having undergone treatment for triple-negative breast cancer in 2018, followed by acute myeloid leukemia and a stem-cell (bone marrow) transplant in 2020, I have a deep understanding of the challenges faced by individuals with life-threatening illnesses and those confronting mortality.  I know the frustrations of navigating the medical system and trying to be an advocate for yourself while you are sick. I am passionate about working with people who live with life-threatening and chronic illnesses. I believe that psychedelic-assisted therapy, in particular, can help individuals find meaning, hope, and joy in their lives, even when facing grief, loss, chronic illness or mortality.